Iridex Corporation and Imperial College Healthcare NHS Trust in London, announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse®? Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6®? Laser and the MicroPulse P3®?

Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. The study, titled "MicroPulse Transscleral Laser Therapy: A Prospective UK Study," is set to expand Iridex's global clinical portfolio, through its commitment to funding essential components of the 3-year study and providing a custom-designed and secure database management system.

The Western Eye Glaucoma Department of the Imperial College Healthcare NHS Trust is the first to implement MicroPulse®? TLT as part of this clinical research registry, adhering to NICE IPG692 guidelines. The registry and study is structured for expanded participation from other UK providers to join the program and build enrollment for large patient cohorts.

Both Iridex and Imperial College Healthcare NHS Trust are dedicated to conducting this study in accordance with the strictest ethical and regulatory standards and look forward to welcoming additional sites to join the program. The collaboration symbolizes the company?s shared vision for advancing medical science with MicroPulse® TLT. It promises significant insights and advancements in glaucoma laser therapy, potentially revolutionizing treatment approaches and enhancing patient care.